Stage III malignant mixed Müllerian tumor of the fallopian tube: A case of 5-year survival after optimal debulking and adjuvant chemotherapy with paclitaxel plus carboplatin

Stage III malignant mixed Müllerian tumor of the fallopian tube: A case of 5-year survival after optimal debulking and adjuvant chemotherapy with paclitaxel plus carboplatin

Bibliographic Details
Main Authors:	Ching-Pei Tsai, Esther Shih-Chu Ho, Yu-Min Ke, Shih-Tien Hsu, Ren-Ching Wang, Chien-Hsing Lu
Format:	Article
Language:	English
Published:	Elsevier 2012-06-01
Series:	Taiwanese Journal of Obstetrics & Gynecology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1028455912000824

Similar Items

Comparison of Efficacy and Safety Between Liposome-paclitaxel plus Carboplatin and Paclitaxel plus Carboplatin on Epithelial Ovarian Cancer
by: HOU Wenjie, et al.
Published: (2018-06-01)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
by: Katsurada N, et al.
Published: (2020-02-01)

Uncommon Manifestations of Endocervical Malignant Mixed Mullerian Tumor with Incidental Bilateral Fallopian Tube Carcinoma
by: Kishan Prasad H L., et al.
Published: (2011-01-01)

Malignancy of fallopian tube
by: Ranjan Agrawal
Published: (2015-01-01)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
by: Toshinobu Hayashi, et al.
Published: (2021-01-01)

Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis
by: Renata Rodrigues da Cunha Colombo Bonadio, et al.
Published: (2018-01-01)

Survival and Side Effects of Cisplatin/Cyclophosphamide and Carboplatin/Paclitaxel Adjuvant Chemotherapy in Stage IC-IV Ovarian Cancer
by: Unedo H Markus, et al.
Published: (2015-04-01)

Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer
by: Aurelio B. Castrellon, et al.
Published: (2018-03-01)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
by: S B Dessai, et al.
Published: (2016-01-01)

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
by: Hamid Attarian, et al.
Published: (2009-07-01)

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
by: Hamid Attarian, et al.
Published: (2009-09-01)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
by: Shinya Sakata, et al.
Published: (2015-01-01)

Primary Fallopian Tube Cancer May Mimic Endometrial Malignancy
by: Chi-Kung Lin, et al.
Published: (2008-06-01)

Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report
by: Hideyuki Niwa, et al.
Published: (2018-01-01)

NEOADJUVANT WEEKLY NAB-PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY DOXORUBICIN PLUS CYCLOPHOSPHAMIDE WITH BEVACIZUMAB ADDED CONCURRENTLY TO CHEMOTHERAPY FOR OPERABLE TRIPLE-NEGATIVE INVASIVE BREAST CANCER
by: Jasgit C. Sachdev, et al.
Published: (2016-05-01)

Metastatic fallopian tube carcinoma presenting as an inguinal hernia
by: Jui-Chun Chang, et al.
Published: (2015-02-01)

Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer
by: Mohammad Mobayed, et al.
Published: (2009-11-01)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
by: Shinichi Tate, et al.
Published: (2021-02-01)

Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models
by: Yanxiu Guo, et al.
Published: (2018-01-01)

Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients
by: Afandi Charles, et al.
Published: (2016-11-01)

Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer
by: Wei-Chun Chen, et al.
Published: (2020-01-01)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
by: Thomas M, et al.
Published: (2017-10-01)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
by: Sally Mullany, et al.
Published: (2020-11-01)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports
by: Tomoyuki Araya, et al.
Published: (2020-12-01)

Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III–IV Ovarian Serous Carcinoma
by: R. Kawaguchi, et al.
Published: (2012-04-01)

Expression of Semaphorin 3F and Its Receptors in Epithelial Ovarian Cancer, Fallopian Tubes, and Secondary Müllerian Tissues
by: Christina D. Drenberg, et al.
Published: (2009-01-01)

Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma
by: Megan Lander, et al.
Published: (2020-05-01)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
by: Kunihiko Funaishi, et al.
Published: (2017-06-01)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
by: Chen-Yu Huang, et al.
Published: (2020-03-01)

Phase 1 study of one-week chemotherapy with paclitaxel and carboplatin in patients with metastatic bladder cancer
by: M. Johansen, et al.
Published: (2020-02-01)

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
by: Madison R. Klavans, et al.
Published: (2020-11-01)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
by: Hirotoshi Yasui, et al.
Published: (2014-08-01)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
by: Lin H, et al.
Published: (2021-07-01)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
by: Ahmed Gamal Elsayed, et al.
Published: (2017-08-01)

Duplication of the fallopian tube
by: R Narayanan, et al.
Published: (2008-01-01)

Fallopian tube disease
by: Cobbett, Charles Newberry
Published: (1890)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015-07-01)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
by: Furubayashi N, et al.
Published: (2020-10-01)

Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers
by: Sereni, Maria Isabella, et al.
Published: (2017)

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
by: Briasoulis Evangelos, et al.
Published: (2010-01-01)